Relpax Patent Expiration

Relpax is a drug owned by Upjohn Manufacturing Ireland Unltd. It is protected by 2 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Aug 29, 2017. Details of Relpax's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6110940 Salts of an anti-migraine indole derivative
Aug, 2017

(7 years ago)

Expired
US5545644 Indole derivatives
Dec, 2016

(7 years ago)

Expired

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Relpax is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Relpax's family patents as well as insights into ongoing legal events on those patents.

Relpax's Family Patents


Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Relpax's generic launch date based on the expiry of its last outstanding patent is estimated to be Aug 29, 2017 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Relpax Generic API suppliers:

Eletriptan Hydrobromide is the generic name for the brand Relpax. 8 different companies have already filed for the generic of Relpax, with Ajanta Pharma Ltd having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Relpax's generic

How can I launch a generic of Relpax before its drug patent expiration? :

You can seek FDA approval to launch a generic drug before the expiration of Relpax's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Relpax's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Given below are the details of the already filed Para IV certificates on Relpax -

Strength Submission Date ANDA(s) Filed First applicant approval Last patent expiry 180 day status
20 mg and 40 mg 29 Mar, 2010 1 29 Aug, 2017 Extinguished





About Relpax

Relpax is a drug owned by Upjohn Manufacturing Ireland Unltd. It is used for treating migraines with or without aura. Relpax uses Eletriptan Hydrobromide as an active ingredient. Relpax was launched by Upjohn in 2002.

Approval Date:

Relpax was approved by FDA for market use on 26 December, 2002.

Active Ingredient:

Relpax uses Eletriptan Hydrobromide as the active ingredient. Check out other Drugs and Companies using Eletriptan Hydrobromide ingredient

Treatment:

Relpax is used for treating migraines with or without aura.

Dosage:

Relpax is available in tablet form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
EQ 40MG BASE TABLET Prescription ORAL
EQ 20MG BASE TABLET Prescription ORAL